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Available online 26 June 2019Background: Betaine is known to act against various biological stresses and its levels were reported to be de-
creased in schizophrenia patients. We aimed to test the role of betaine in schizophrenia pathophysiology, and
to evaluate its potential as a novel psychotherapeutic.
Methods: Using Chdh (a gene for betaine synthesis)-deficient mice and betaine-supplemented inbred mice, we
assessed the role of betaine in psychiatric pathophysiology, and its potential as a novel psychotherapeutic, by
leveraging metabolomics, behavioral-, transcriptomics and DNA methylation analyses.
Findings: The Chdh-deficient mice revealed remnants of psychiatric behaviors along with schizophrenia-related
molecular perturbations in the brain. Betaine supplementation elicited genetic background-dependent improve-
ment in cognitive performance, and suppressed methamphetamine (MAP)-induced behavioral sensitization.
Furthermore, betaine rectified the altered antioxidative and proinflammatory responses induced by MAP and
in vitro phencyclidine (PCP) treatments. Betaine also showed a prophylactic effect on behavioral abnormality in-
duced by PCP. Notably, betaine levels were decreased in the postmortem brains from schizophrenia, and a
coexisting elevated carbonyl stress, a form of oxidative stress, demarcated a subset of schizophrenia with “beta-
ine deficit-oxidative stress pathology”. We revealed the decrease of betaine levels in glyoxylase 1 (GLO1)-
deficient hiPSCs, which shows elevated carbonyl stress, and the efficacy of betaine in alleviating it, thus
supporting a causal link between betaine and oxidative stress conditions. Furthermore, a CHDH variant,
rs35518479,was identified as a cis-expression quantitative trait locus (QTL) for CHDH expression in postmortem
brains from schizophrenia, allowing genotype-based stratification of schizophrenia patients for betaine efficacy.
Interpretation: The present study revealed the role of betaine in psychiatric pathophysiology and underscores the
potential benefit of betaine in a subset of schizophrenia.
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for Medical Research and Development) under Grant Numbers JP18dm0107083 and JP19dm0107083 (TY),
JP18dm0107129 (MM), JP18dm0107086 (YK), JP18dm0107107 (HY), JP18dm0107104 (AK) and
JP19dm0107119 (KH), by the Grant-in-Aid for Scientific Research on Innovative Areas from the MEXT under
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. This is an open access article under1. Introduction
There is an urgent need for novel medicines with new actions for
psychiatric illness, because almost all of the present therapeutics arethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Almost all of the presently available antipsychotics are designed to
act on the monoamine receptors or transporters, and their limited
efficacy demands novel drug development paradigms.
Metabolomic profiling approach in disease biology has been instru-
mental in deciphering mechanistic insights into disease patho-
physiology, enabling the identification of novel therapeutic
targets. Altered brain metabolome has been a consistent observa-
tion in schizophrenia, and it is also reflected in the peripheral sam-
ples. Betaine (glycine betaine or trimethylglycine) is one such
metabolite that was observed to be decreased in the plasma sam-
ples of patientswith first-episode schizophrenia. This prompted us
to test the role of betaine in schizophrenia pathophysiology, and to
evaluate its potential as a novel psychotherapeutic, by leveraging
metabolomics, behavioral-, transcriptomics and DNA methylation
analyses.
Added value of this study
We showed that the lack of betaine, stemmed from the genetic
loss of Chdh activity in mice, resulted in remnants of psychiatric
behaviors and schizophrenia-related molecular perturbations in
the brain. Interestingly, the betaine supplementation elicited ge-
netic background-dependent improvement in cognitive perfor-
mance. Furthermore, betaine supplementation showed
psychotropic action in pharmacological animal models of schizo-
phrenia and rectified the altered antioxidative and proinflammatory
responses characteristic of themodel. In agreementwith these ob-
servations, betaine levels were seen decreased in the postmortem
brains from schizophrenia, and a coexisting elevated carbonyl
stress (a form of oxidative stress) demarcated a subset of schizo-
phrenia with “betaine deficit-oxidative stress pathology”. We fur-
ther showed that the decreased betaine levels were consistent
with the elevated carbonyl stress, in glyoxylase 1-deficient hiPSCs
and betaine supplementation was efficacious in alleviating ele-
vated carbonyl stress.Wealso identified a cis-expression quantita-
tive trait locus (QTL) for CHDH expression in postmortem brains
from schizophrenia, enabling genotype-based stratification of
schizophrenia patients for betaine efficacy.
Implications of all the available evidence
The present study demonstrated that deficits of betaine levels in
the brain contribute to the psychiatric pathophysiology and also re-
vealed the potential benefit of betaine as a psychotherapeutic in a




























Methionine Cycle Betaine biosynthesis
Transsulfation
Fig. 1. Methionine–homocysteine cycle and biosynthesis of betaine. The methionine–
homocysteine cycle, betaine biosynthesis pathway, and transsulfation pathway are
schematically presented. Met, methionine; SAM, S-adenosylmethionine; Met sulfoxide,
methionine sulfoxide; –CH3,methyl group; SAH, S-adenosylhomocysteine; Hcy, homocys-
teine; methyl-THF, 5-methyltetrahydrofolate; MS, methionine synthase; CBS, cystathio-
nine beta-synthase; CGL, cystathionine beta-lyase; MSRA, methionine sulfoxide
reductase A; MSRB1/2, methionine sulfoxide reductase B1/2.
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there is a substantial population where the presently available drugs
are unsatisfactory [2]. Altered brainmetabolomeand its reflection in pe-
ripheral samples is a growing observation in schizophrenia,which could
be beneficial for decipheringmolecular pathophysiology of schizophre-
nia and thereby identifying novel druggable targets [3–5]. Betaine (gly-
cine betaine or trimethylglycine) is a metabolite that is reported to be
decreased in the plasma sample of patients with first-episode schizo-
phrenia (FESZ) [3]. In their report, they examined the plasma metabo-
lites from FESZs and healthy controls in order to identify biomarkers
for schizophrenia. The reduction of the betaine level was replicated in
the second sample set, suggesting future use of betaine as a clinical bio-
marker for schizophrenia.In vertebrates, betaine is ingested from the diet [5] and is also endog-
enously synthesized in mitochondria from its precursor choline using
choline dehydrogenase (CHDH) (Fig. 1) [4]. To date, several biological
functions of betaine have been proposed, which include (i) osmotic reg-
ulator (compatible solute) [6,7]; (ii) antioxidative/anti-inflammatory
activity [8]; (iii) supplier of methyl donor S-adenosylmethionine [9];
and (iv) mitigator of noxious elevated homocysteine [10] (Supplemen-
tary Fig. 1). The latter two are endowed through acceleration of the
turnover of the methionine–homocysteine cycle (constituting
one‑carbon metabolism together with the folate cycle), where betaine
serves as a substrate in the betaine–homocysteine S-methyltransferase
(BHMT) reaction, converting homocysteine to methionine [11] (Fig. 1).
In this study, we aimed to test the role of betaine in schizophrenia
pathophysiology, and toevaluate its potential as anovel psychotherapeu-
tic. Using Chdh (a gene for betaine synthesis)-deficientmice and betaine-
supplemented inbred mice, we assessed betaine-related metabolite dy-
namics and the effects of betaine deficits and supplementation, by
leveragingmetabolomics, behavioral-, transcriptomics and DNAmethyl-
ationanalyses. Further,wequeriedwhetherbetainedeficits and the asso-
ciated pathology are observed in postmortembrains from schizophrenia.
We examined the efficacy of betaine in human induced pluripotent stem
cells (hiPSCs)manifesting elevated carbonyl stress,which is a tributary of
oxidative stress and caused by accumulation of “advanced glycation end
products” (AGEs) [12] (Supplementary Fig. 2). The enhanced carbonyl
stress is known to underlie the pathophysiology of a subset of schizo-
phrenia [13,14]. Lastly, we searched for genetic variants that can be
used as a biomarker to predict “betaine-responders”.
2. Materials and methods
See the Supplementary information for the details of the techniques
outlined below.
2.1. Study approval
All the animal experiments were performed in compliance with rel-
evant laws, and guidelines were approved by the Animal Ethics
434 T. Ohnishi et al. / EBioMedicine 45 (2019) 432–446Committee at RIKEN (permission numbers: H29–2-204 [3] and
2016–058 [4]) and the Chiba University Institutional Animal Care and
Use Committee (permission number: 31–342). Human induced plurip-
otent stem cell (hiPSC) study was approved by the Human Ethics Com-
mittee at RIKEN for iPSC study (Wako-daisan 25–14). The subject for
hiPSC study gave informed, written consent to participate in the study
after being provided with, and receiving an explanation of study proto-
cols and objectives. Experiments in postmortem brain sampleswere ap-
proved by Fukushima Medical University, Japan (1685 and 2381) and
Niigata University School of Medicine, Japan (G2015–0827). All proce-
dures of postmortem brain study were carried out with the informed
written consent of the next of kin.2.2. Animals
The inbred C57BL/6NCrl (B6N) and C3H/HeNCrl (C3HN) mouse
strains were obtained from Japan's Charles River Laboratories (Yoko-
hama, Japan). The animals were housed in groups of four in standard
cages, in a temperature and humidity-controlled room with a 12 h
light/dark cycle (lights on at 08:00). The animals had free access to stan-
dard lab chow and tap water. All animal experiments were done using
male animals (six to 15 animals/group, depending on experiments) be-
tween 9:30 am and 5:00 pm. In the study using the Chdh KO mice, the
wild-type littermates by intercross between heterozygotes were used
as control. All the analyses were conducted between nine and
14 weeks of age, except for the novel object recognition test (NORT)
using the ICR strain (purchased from Japan SLC, Hamamatsu, Japan),
which was started at 7 weeks of age.2.3. Postmortem brain samples
Postmortem brain tissues (BA17; Brodmann Area 17) from schizo-
phrenia and age-matched control sampleswere obtained from the Post-
mortem Brain Bank of Fukushima for Psychiatric Research and Brain
Research Institute, Niigata University, Japan (in total n= 24 for schizo-
phrenia and n = 31 for control) [15–17]. Each individual with schizo-
phrenia fulfilled the diagnostic criteria established by the American
Psychiatric Association (Diagnostic andStatisticalManual ofMental Dis-
orders: DSM-IV) and had no history of any other neurological disorder
or substance abuse. The agematched control sampleswerewith no his-
tory of neuropsychiatric disorders. Also, neuropathological evaluation in
the control brain samples ruled out any pathological abnormalities
characteristic of neurological disorders, though some brains showed in-
dication of mild senility.2.4. Generation of Chdh-deficient mice
The Chdh-deficient mice were generated by the genome editing
methodology using the CRISPR/Cas9 nickase.2.5. Estimation of betaine and other metabolites
Choline, methionine, betaine, cystathionine, cystine, S-
adenosylmethionine (SAM), and S-adenosylhomocysteine (SAH) levels
were estimated by liquid chromatography-mass spectrometry (LC/MS).
Cysteine, homocysteine and glutathione (GSH) were measured as their
reduced formsbyhigh performance liquid chromatography (HPLC). The
plasma levels of blood urea nitrogen (BUN), creatinine (CRE), aspartate
transaminase (AST), alanine transaminase (ALT), lactate dehydrogenase
(LDH) and cholinesterase (CHE) were measured using dry-chemistry
analysis (Fuji Dri-Chem 3500 V; FUJIFILM Medical Co., Ltd., Tokyo,
Japan).2.6. Behavioral analyses
All behavioral tests relevant to psychiatric illnesses, except for the
methamphetamine (MAP)-induced behavioral sensitization test, were
performed according to the previously published methods [18]. For
the MAP-induced behavioral sensitization test, see the Supplementary
Methods. When the effect of betaine supplementation on impairment
of the NORT performance by chronic PCP treatment was examined,
male ICR mice at 7 weeks of age were given betaine (2.5% as
monohydrate in drinking water) or water until the day 29. Either PCP
(10 mg/kg/day) or vehicle (saline) was subcutaneously administered
once a day to the ICR mice from the day 15 to the day 26. The NORT ex-
periment was started at the day 26 as described elsewhere [19]. The
mice were habituated in the experimental environment for 3 days.
The training and test sessions were conducted at the days 29 and 30,
respectively.
2.7. DNA methylation analysis
DNAmethylation in frontal cortex of Chdh knockout (KO)mice (n=
6) and wild-type (WT) control (n = 6) was performed by targeted
methylation sequencing of 109Mb ofmouse genomic regions, which in-
cluded CpG islands, known tissue-specific differentially methylated re-
gions (DMR), open regulatory annotations and Ensembl regulatory
features.
2.8. RNA-seq analysis
Transcriptome analysis in frontal cortical brain region was per-
formed by RNA-seq in (a) Chdh KO mice (n = 6) versus WT controls
(n = six), and (b) B6N and C3HN mouse strains administered betaine
in comparison to respective controls administered water (n = 6 in
each group).
2.9. Real-time quantitative reverse transcription (RT)-PCR
Targeted gene expression was measured by real-time quantitative
RT-PCR using TaqMan assays [20].
2.10. Rat primary cortical neuron culture
Rat primary cortical neuron was isolated from the cortices of
Sprague-Dawley rats (obtained from Japan's Charles River) at embry-
onic day 18.5 (E18.5) as described previously [21]. For the details, see
the Supplementary Methods.
2.11. Establishment of GLO1-deficient hiPSCs
Human induced pluripotent stem cells (hiPSCs) were established
from peripheral blood mononuclear cells using Sendai virus vector
[22]. Isogenic GLO1-deficient hiPSCs were generated using CRISPR/
Cas9-mediated genome editing.
2.12. Carbonyl stress assay
Carbonyl Stress was analyzed by Western blotting using anti-AGE
antibody. See the Supplementary Methods.
2.13. Cis-eQTL analysis
For eQTL analysis, we selected BHMT1, CHDH and GLO1 and
downloaded eQTL data for the brain tissues from GTEx portal (https://
gtexportal.org/home/) (Release V7; dbGaP Accession phs000424.v7.
p2). The significant eQTL variants with high effect size were selected
and filtered for minor allele frequency (MAF) N 30% in Japanese popula-
tion with reference to the Tohuku megabank genome variation data
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ac.jp/201902/downloads) (3.5KJPNv2). These variants were further
pruned for linkage disequilibrium (LD) status (r2 b 0.4), yielding vari-
ants from independent LD blocks. The shortlisted variants (4 in BHMT,
3 in CHDH and 3 inGLO1)were genotyped in schizophrenia postmortem
brain tissues (BA17) (n = 50) by TaqMan SNP genotyping Assays [23].
Gene expression was measured by real-time quantitative RT-PCR
using TaqManassays. Outliers (more or less thanmean±2SD)were ex-
cluded. Association of the variants with the gene expression andmetab-
olites were tested by one-way ANOVA and Student's t-test.2.14. Statistical analysis
All values in the figures represent the mean ± SEM. Statistical anal-
ysis and graphical representation were performed using GraphPad
Prism 6 (GraphPad Software). The total sample size (n) was described
in the respective figure legends. Statistical significance was
determined using a two-tailed Student's t-test. Whenmultiple compar-
isonswere needed, one-way or two-way ANOVAwith Fisher's least sig-
nificant difference (LSD) test, Tukey's multiple comparison test,
Bonferroni's correction, or Dunnett's multiple comparison test was
used as indicated in the figure legends. A P value of b0.05 was consid-
ered as statistically significant.3. Results
3.1. Generation of Chdh-deficient mice
In vertebrates, betaine is biosynthesized by two biochemical reac-
tions (Fig. 1). The first step, oxidation of choline to betaine aldehyde,
is mediated by choline dehydrogenase encoded by the Chdh/CHDH
gene, and in turn, betaine aldehyde is converted into betaine by betaine
aldehyde dehydrogenase. To create an animal model with lowered be-
taine level, the first coding exon, exon 2 of the Chdh gene, was targeted
by the CRISPR/Cas9n on the genetic background of the inbred B6N
mouse (Supplementary Fig. 3a and b). Homozygotes for the gene dis-
ruption seemed healthy and revealed no clear abnormalities in growth
or morphology (Supplementary Fig. 3c).3.2. Betaine levels and effects of betaine supplementation in Chdh-deficient
mice
The disruption of the Chdh gene significantly reduced the betaine
levels in the frontal cortex from ~20 pmol/mg tissue to levels near de-
tection limit (p b 0.01) (Fig. 2a). This suggested that the endogenous
biosynthesis rather than intake from diet maintained the level of beta-
ine in the brain. Supplementation of betaine via drinking water (2.17%
betaine, 2.5% as betaine monohydrate) for 3 weeks, significantly in-
creased betaine level in the brain of both the WT (p b 0.0001) and
gene-disrupted mice (p b 0.001) (Fig. 2a), indicating that peripherally-
administered betaine can penetrate the blood–brain barrier and enter
the brain.
In the plasma, however, betaine levels were near detection limit in
both the WT and Chdh-deficient mice in our measurement system
(Fig. 2b). Median betaine concentration in plasma in humans has been
reported to be 27.8 pmol/L [24], which was in the detectable range in
our system. Therefore, the peripheral betaine turnover could be differ-
ent between mice and humans. Although the plasma betaine levels
were increased after the betaine supplementation, the increments
were not significant in both the WT and KO animals (Fig. 2b), partially
due to widely variable betaine levels in the betaine-administered
animals.3.3. No adverse effects of betaine deficiency in kidney and liver functions
Since the kidney and liver showhigh expression of Chdh and contain
abundant levels of betaine [25],we examined the effects of gene disrup-
tion with respect to their functions. The gene disruption elicited a trend
of decreased betaine levels (p b 0.1) (Fig. 2c). Betaine levels in the kid-
ney of KOmice were replenished to those of WT littermates upon beta-
ine supplementation (Fig. 2c). Betaine in the liver plays a crucial role in
one‑carbonmetabolism [25], but no impairments of liver function were
observed by the Chdh disruption, as shown by the unaltered plasma
levels of AST, ALT, LDH, CHE, BUN or CRE (Supplementary Table 1). Fur-
thermore, the total levels of glutathione (GSH+GSSG)were not altered
by the gene disruption (Fig. 2d and e) in the brain or plasma, suggesting
that the lack of Chdh activity itself did not invoke a serious oxidative
stress condition in mice.
3.4. Levels of metabolites in methionine–homocysteine cycle in the brain
Among the metabolites in the methionine–homocysteine cycle
that were driven by betaine (Fig. 1), levels of homocysteine, a potent
oxidant, changed differentially between the plasma and brain. In the
plasma, homocysteine concentration was increased by the disruption
of Chdh (p b 0.01), and it showed a trend towards WT level (p b
0.1) upon betaine supplementation (Fig. 2f). While in the brain (fron-
tal cortex), homocysteine levels were unchanged among the groups
(Fig. 2g). We also examined the two inbred mouse strains, B6N (the
same genetic background with the Chdh-deficient mouse) and C3HN,
each of which manifested two extremities for prepulse inhibition
function (B6N, highest; C3HN, lowest), a schizophrenia and other
mental disorder-related endophenotype [26]. Total homocysteine
levels in the brain after betaine supplementation was also unchanged
in the two inbred strains (Fig. 2h). The results suggest that homocys-
teine levels in the brain are robustly maintained constant against per-
turbation of peripheral betaine levels. Interestingly, the cellular
methylation capacity deduced from the SAM/SAH ratio [27,28],
showed a significant increase (p b 0.05) upon betaine supplementa-
tion in the B6N WT brain (Fig. 2i), suggesting a possibility that exter-
nally administered betaine could have an impact on the methylation
capacity to some extent.
3.5. DNA methylation and transcriptome analyses in the Chdh-deficient
mice
To explore the impact of betaine on DNA methylation status, a
targeted analysis of methylated genomic regions at single base pair res-
olution in the frontal cortex from Chdh-deficient mice was performed.
The results revealed no statistically significant differences in DNAmeth-
ylation when compared to the WT mice after multiple corrections (q
value N0.05; Fig. 3a, Supplementary Table 2). As an exploratory ap-
proach, we selected differentially methylated gene promoters,
employing a conservative estimate of p b 0.05 to test the enrichment
of canonical pathways and gene ontologies (Fig. 3b, Supplementary
Table 3). Significant enrichmentwas observed for “tight junction signal-
ing” and “sertoli cell-sertoli cell junction signaling” pathways for
hypermethylated gene promoters, the latter could be related to the in-
fertility phenotype of Chdh-deficient mice [29]. In the case of
hypomethylated promoters, cytoskeletal dynamics pathways such as
“integrin signaling” and “ephrin receptor signaling” were enriched
(Fig. 3b).
Regarding the transcriptomic level changes elicited by the Chdh dis-
ruption in the frontal cortex, a total of 851 genes were significantly dys-
regulated (546 upregulated and 305 downregulated) in the KO
compared to theWT littermates (p b 0.05) (Fig. 3c, and Supplementary
Table 4). The Ingenuity Pathway Analysis showed significant enrich-
ment for molecular pathways, for example, eukaryotic initiation factor
2 (eIF2) signaling, protein ubiquitination pathway, regulation of
436 T. Ohnishi et al. / EBioMedicine 45 (2019) 432–446eukaryotic initiation factor 4 (eIF4) and p70 S6 kinase signaling, and
mammalian target of rapamycin (mTOR) signaling for the downregu-
lated genes (p b 0.05) (Fig. 3d, and Supplementary Table 5). These re-
sults were in accordance with the reduced protein synthesis observed
in schizophrenia, which involve the eIF2α, eIF4 and mTOR signaling
pathways [30]. The upregulated genes were also enriched for molecular
pathways potentially related to the schizophrenia pathophysiology:
glutamate receptor signaling and synaptic long-term depression
(Fig. 3d, bottom). The upregulation results might be compensatory
ones against reduced protein synthesis. Collectively, the altered molec-
ular deficits by the Chdh disruptionmay represent a “molecular precur-
sor signature” [31] underling schizophrenia pathophysiology.
3.6. Chdh-deficient mice displayed remnants of depressive behavior
We examined 15 distinct behavioral phenotypes relevant to psychi-
atric illnesses (Supplementary Fig. 6). In the forced swim test, immobil-
ity time at bin 5 (4-5 min) was significantly prolonged (p b 0.05), and


















































































































Fig. 2. Effects of Chdh-deficiency and betaine supplementation on the metabolite contents. Me
mate control (WT) mice with (betaine) or without (water) chronic betaine supplementation.
which were restored by betaine supplementation. (b) In plasma, betaine levels were not statis
the kidney ofChdh-deficientmice andwere restored toWT level. Total glutathione (GSH) conten
differences among the tested groups. (f) Total plasma homocysteine increased in the Chdh-defic
plementation; however, in the brain, the levels of total homocysteine were unchanged in the
significantly increased with betaine supplementation in WT B6N mice. Data represent mean
four groups. n = five to seven per group.Chdh-deficient mice compared to the WT littermates (Figs. 3e and f),
suggesting a depressive trait in the gene-deficientmice. In the other be-
havioral tests, no significant differenceswere observed between theWT
and Chdh-deficientmice (Supplementary Fig. 6). The limited behavioral
deficits elicited by the Chdh disruption could be partly due to the fact
that betainewas not completely depleted from thewhole body, because
betaine was available from the diet or through intestinal microflora
[32,33].
3.7. Effects of betaine supplementation in inbred mouse strains
To determine the therapeutic potential of betaine in psychiatric dis-
orders, betainewas administered via drinkingwater (2.17% betaine) for
3 weeks to the two inbredmouse strains; B6N and C3HN. In general, ef-
ficacy of drugs, in particular neurotropics, varies with respect to the in-
dividual patients or genetic backgrounds. The same 15 distinct
behavioral phenotypes as evaluated in the Chdh-deficient mice were
measured.Notably, betaine supplementation elicited thedifferential be-
havioral effects in the two strains. In the novel object recognition testKidney
WT Homo
Betaine

























































tabolite contents were measured in the Chdh-deficient (Homo) and wild-type Chdh litter-
(a) Betaine levels were significantly reduced in the frontal cortex of Chdh-deficient mice,
tically significant among the tested groups. (c) Betaine levels were drastically reduced in
ts (GSH+GSSG), in the (d) brain and (e) plasma did not reveal any statistically significant
ient micewhen compared toWT, and showed a trend towardsWT level after betaine sup-
tested groups (g-h). (i) SAM/SAH ratio, indicating the cellular methylation potential, was
± SEM. *p b 0.05, **p b 0.01, ***, p b 0.001; Tukey's multiple comparison test among the
Fig. 3.DNAmethylome, transcriptome andbehavioral analyses of Chdh-deficientmice. (a) TargetedDNAmethylation analysis across the genome, from the frontal cortex of Chdh-deficient
mice, did not reveal any statistically significant differences (after correcting formultiple tests; q value N0.05)when compared to thewild-type control. (b) Pathway analysis of geneswith a
p b 0.05 (uncorrected) indicated an enrichment of “tight junction signaling” and “sertoli cell-sertoli cell junction signaling” pathways for hypermethylated promoters, implicated in sper-
matogenesis. Hypomethylated genes were enriched for pathways involving cytoskeletal dynamics; n= six in each group. (c) Volcano plot shows differentially expressed genes between
ChdhKOmice andwild type controls from frontal cortex; n=six in each group. Green and blue dashed lines indicate p value thresholds of 0.05 and 0.01, respectively. Top hits among the
differentially expressed genes (p b 0.01 and absolute fold-change N2) are highlighted in the plot. (d) Differentially expressed genes (p b 0.05) were analyzed for the enriched canonical
pathways, which revealed enrichment for signaling pathways involved in the regulation of translational control and protein synthesis/degradation, for downregulated genes.
(e) Results of forced swim test are presented. 1 bin corresponds to 1 min. Note that the Chdh-deficient mice showed increased immobility in bin five (p = 0.01). Data represent mean
± SEM. *p b 0.05, **p b 0.01; Fisher's Least Significant Difference (LSD) test. n=21 per group. (f) Cumulative values of immobility time for fiveminutes (bins two to six) were calculated.
Note that KO homozygotes revealed a trend of increase in immobility time (p = 0.09). Data represent mean ± SEM. n = 21 per group.


















































































































































































438 T. Ohnishi et al. / EBioMedicine 45 (2019) 432–446(NORT), B6N mice showed significantly longer stay time at a novel ob-
ject in the retention session in the betaine-supplemented group com-
pared to the water-drinking control, suggesting improved cognitive
memory performance in the B6N strain (Fig. 4a). In contrast, C3H
mice showed no significant improvement in the performance bybetaine supplementation (Fig. 4a). Althoughwe donot know the reason
for the difference between the two strains, itmay be related to themuch
lower preference to a novel object at the basal level when compared to
familiar one in C3H mice. Both B6N and C3HN mouse strains showed
better performance with betaine supplementation in the Y-maze test,
439T. Ohnishi et al. / EBioMedicine 45 (2019) 432–446which assessed the spatial working memory ability, compared to the
control (Fig. 4b). However, no significant changes were observed in
theNORT or Y-maze test, resulting from the genetic loss of Chdh activity
(Supplementary Fig. 6), potentially due to the supplementation of beta-
ine from the chow and/or intestinal bacterialflora. Therewere no signif-
icant differences between the betaine-administered and control groups
in B6N or C3HN animals in the other behavioral tests, and importantly
no behavioral measures were impaired by betaine treatments in both
strains (data not shown). No gross abnormalities in blood chemistry
were also observed (data not shown).
Transcriptome analysis of the frontal cortex revealed that the pat-
terns of gene expression caused by betaine were distinct between the
two strains, presumably stemming from the underlying genetic differ-
ences and aligning with their behavioral differences (Figs. 4c, d, and
Supplementary Table 6). Interestingly, theprincipal component analysis
(PCA) of transcriptome data revealed clear segregation of mouse strains
in relation to betaine supplementation (based on principal components
1 and 2) (Fig. 4e). The principal components 3 and 4 could clearly dis-
criminate the effect of betaine supplementation irrespective of strain
differences (Fig. 4f). Gene ontology enrichment analysis of genes
whose expression was positively correlated with PCA loading factor in
these principal components revealed biological processes relevant for
the cognition, memory, and neurodevelopment related terms (Supple-
mentary Table 7). Meanwhile, certain common molecular phenotypes
were also evident (Supplementary Fig. 7, Supplementary Table 8, and
9). These results highlight an interaction of genetic background × drug
(betaine). Gene ontology analysis of upregulated genes by betaine sup-
plementation in both strains identified mitogen-activated protein ki-
nase (MAPK) signaling cascade (Supplementary Table 8), where
relevant genetic impairments have been documented in schizophrenia
[34].
3.8. Effects of betaine supplementation onMAP-induced behavioral sensiti-
zation and gene expression
We next examined whether betaine could perform psychotropic ac-
tion in ananimalmodel of schizophrenia by leveragingbehavioral sensi-
tization paradigm, where repeated administration of psychostimulants
in rodents can enhance the stimulating effect on locomotor activity.
This behavioral paradigm is assumed to model positive symptoms of
schizophrenia and the relapse process [35]. It is of note that peripheral
betaine concentration in schizophrenia was inversely correlated with
positive symptom scores of the PANSS (Positive andNegative Syndrome
Scale) test [3]. Water or betaine (2.17%) was administered 3 weeks be-
fore methamphetamine (MAP) injection throughout to the day of MAP
challenge (Fig. 5a). In the B6Nmice, the challenge injection of MAP elic-
ited enhanced locomotor activities compared to those of the first MAP
administration in both water and betaine groups (Fig. 5b). Remarkably,
betaine suppressed the degree of elevation in the locomotor activities,
which was counted as the differences between the challenge MAP-
induced activities and the first MAP-induced activities (p b 0.01)
(Fig. 5c). In the C3HN mice, repeated MAP injections did not evoke a
marked locomotor sensitization (Fig. 5d). Accordingly, the effect of beta-
ine on the suppression of behavioral sensitization was not clear in the
C3HNmice (Fig. 5e), demonstrating the different pharmacogenetic pro-
files between the two strains.
While the gene expression analyses revealed that betaine deficits
and supplementation influenced multiple schizophrenia-relevant tran-
scriptome signatures, we specifically focused on the gene expressionsFig. 4. Betaine supplementation improved cognitive performance and elicited gene expression
with (+) or without (−) chronic betaine supplementation in two inbred strains, B6N and C3H
spatial memory performance. Data represent mean ± SEM. *p b 0.05; Student's t-test. n= sev
uponbetaine supplementation in (c) B6N and (d) C3HNmicewhen compared to the controls th
respectively. Top hits among the differentially expressed genes (p b 0.01 and absolute fold-chan
(PC 1 vs. 2) shows clear segregation of B6N and C3HNmouse strains, and (f) PC 3 vs. 4 shows se
in each group.relevant to oxidative stress and neuroinflammation in the MAP model,
because [1] such mechanism has been presumed as a pathophysiologi-
cal component of behavioral sensitization [36] and schizophrenia [37],
and [2] betaine's potency of antioxidant/anti-inflammatory activity is
proposed (Supplementary Fig. 1) [8]. It is suggested that betaine could
promote nonenzymatic antioxidant activity through the accelerated
turnover of methionine in the methionine–homocysteine cycle. Methi-
onine can act as a scavenger of reactive oxygen species (ROS) [38], and
oxidizedmethionine, methionine sulfoxide, can be reduced back tome-
thionine bymethionine sulfoxide reductase A (MSRA), B1 (MSRB1) and
B2 (MSRB2) (Fig. 1) [39]. Repeated MAP pretreatments coordinately
dampened the expressions of antioxidant genes (Gpx1, Gpx4, Sod1,
Msrb1, Msrb2 and Mpst) (p b 0.05) induced by the MAP challenge, and
in contrast upregulated the proinflammatory gene Nos2 (p b 0.05),
from the comprehensive panel of genes tested (Fig. 5f, Supplementary
Table 10 and Supplementary Fig. 8). Betaine cotreatment antagonized
the effects of repeatedMAP pretreatments on the expression ofmultiple
antioxidant genes (p b 0.05 for Gpx4, Sod1, Msrb1 and Msrb2; p = 0.05
for Mpst) (Fig. 5f). Betaine cotreatment also revealed a trend towards
lowered response of proinflammatory gene expression (Nos2, p =
0.06) after the MAP challenge (Fig. 5f). These results suggest that
betaine's action against MAP-induced sensitization involves, at least in
part, antioxidant/proinflammatory response system.
3.9. Altered oxidative stress and proinflammatory conditions, and working
memory deficit were rescued by betaine administration in in vitro and
in vivo phencyclidine models
We further pursued betaine's action against oxidative stress condi-
tions in in vitro phencyclidine (PCP) model. Chronic administration of
PCP, a noncompetitive N-methyl-D-aspartate (NMDA) receptor blocker,
produces schizophrenia-like behaviors in humans [40]. This psychoto-
mimetic effect is known to be partly associated with oxidative stress
given by PCP [19]. Because the deteriorating effect of PCP on neuronal
system is also observed in the primary neuron culture [41], we exam-
ined the expressional changes of the same genes as in the MAP treat-
ment experiments, plus Sod3 (this gene is expressed in rat brain but
not in mouse brain), in this paradigm (Fig. 6a). Among those genes,
the expressions of Nfe2l2, Rela, Cat, Gpx1, Sod2, Sod3, Cth, Tnf, Nfkb1
and Nos2 showed coordinate upregulation (p b 0.05) under the PCP (1
μM) exposure (Fig. 6b, also see Supplementary Fig. 9). And notably,
the addition of betaine (500 μM) led to significant expressional suppres-
sion (Fig. 6b). These results demonstrate again a role of betaine in the
antioxidant and proinflammatory system.
As a next step, we evaluated the effect of betaine on behavior in an
in vivo PCP model (Fig. 6c). ICR mice chronically treated with PCP
showed significantly reduced novel object recognition preference in
the NORT paradigm as previously reported [19], most likely
representing a working memory deficit (Fig. 6d). Intriguingly, the pre-
treatment of mice with betaine ameliorated the damaging effect of
PCP (p b 0.001) (Fig. 6d).
3.10. Analyses of betaine levels and carbonyl stress in postmortem brain
samples
Next, we asked whether betaine-related pathology can be seen in
schizophrenia. Interestingly, reduced levels of betaine were observed
in the postmortem brain tissue from patients with schizophrenia
when compared to the controls (Fig. 7a), while the other metabolitesal changes. (a) Novel object recognition test (NORT), and (b) Y-maze test were conducted
N. Mouse strains displayed genetic background-dependent improvement in cognitive and
en to ten per group. Volcano plot shows differentially expressed genes from frontal cortex
atwere fedwater. Green andblue dashed lines indicate P-value thresholds of 0.05 and 0.01,
ge N2) are highlighted in the plot. (e) Principal component analysis of transcriptome data
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Fig. 5. Betaine suppressed methamphetamine-induced behavioral sensitization and restored altered oxidative stress/neuroinflammatory conditions. (a) Methamphetamine (MAP)
sensitization tests were conducted with (+) or without (−) chronic betaine supplementation in two inbred strains, B6N and C3HN. The activities by first-day injection and challenge
injection, and the differences in the locomotor activities “Challenge – Day1” [(locomotor activity induced by challenge injection)− (locomotor activity induced by first-day injection)]
are presented (b–e). Betaine supplementation suppressed MAP-induced sensitization in B6N mouse (b, c); whereas, C3HN was not susceptible to the MAP-induced sensitization when
compared to B6N (d, e). Data represent mean ± SEM. *p b 0.05, **p b 0.01, *** p b 0.001, **** p b 0.0001; Bonferroni's multiple comparison test after repeated ANOVA in (b, d), and
Student t-test in (c, e); n = 12 per group. (f) After B6N mice received repeated MAP injections followed by challenge injection, expressions of antioxidant and proinflammatory genes
in the frontal cortex were examined. Data represent mean ± SEM. *p b 0.05, **p b 0.01, *** p b 0.001; Bonferroni multiple comparison test between two preset pairs: Cont vs. MAP, and
MAP vs. MAP+B; n = 5-6, per group. Cont, control (H2O + repeated saline + MAP challenge); MAP, methamphetamine (H2O + repeated MAP + MAP challenge); MAP+B, metham-
phetamine + betaine (betaine + repeated MAP + MAP challenge).
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Fig. 6. Betaine alleviates PCP-induced gene expressional changes in a primary culturemodel and impairment of theNORT performance inmice. (a) After the preparation and incubation of
rat cortical neurons, they were maintained in the absence of PCP, or in the presence of PCP (1 μM) or PCP (1 μM) plus betaine (500 μM) for 11 days. (b) Total RNAswere prepared for real
time RT-PCR to examine expression of each gene (see the text for the details). Data representmean± SEM. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001; Tukey's multiple comparison
test. C; control (absence of PCP), P; PCP, B+P; betaine+PCP. (c) Schematic representation of the experimental schedule ofNORT. The ICRmicewere used for this experiment. The training
and test sessions were conducted in the days 29 and 30, respectively. Mice were given drinking water with or without 2.5% betaine monohydrate between days 1 and 30. Mice were
subcutaneously injected with PCP or vehicle (saline) once a day between days 15 and 26. (d) Novel object recognition test (NORT). Data are shown as means with error bars
representing SEM (n = 7-8/group). *** p b 0.001; Tukey's multiple comparison.
441T. Ohnishi et al. / EBioMedicine 45 (2019) 432–446remained unchanged (Figs. 7b-g) [15–17] (Supplementary Table 11).
SAM contents showed a decreased trend (p b 0.1), whereas SAH levels
were unaltered in the schizophrenia group, resulting in reduced SAM/
SAH ratio in the schizophrenic brain (p b 0.01) (Figs. 7h-j), which can
be linked to the decreased betaine levels (Fig. 1). The betaine levels orthe SAM/SAH levels were not affected by the amounts of antipsychotics
taken (Supplementary Table 12).
To investigate the relationship between betaine system abnormality
and oxidative stress conditions in schizophrenia,we specifically focused
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Fig. 7.Measurements of metabolite contents and advanced glycation end products (AGEs) in postmortem brain samples from schizophrenia. (a) Betaine levels are significantly reduced in
postmortem schizophrenic brain samples. No othermetabolites such as (b) cystine, (c) total Cys, (d)methionine (Met), (e) total Hcy, (f) cystathionine (Cysta), (g) total glutathione (GSH
+ GSSG), (h) S-adenosylmethionine (SAM), and (i) S-adenosylhomocysteine (SAH) were significantly different between schizophrenia cases and controls. (j) The ratio of SAM to SAH
(SAM/SAH) was decreased in schizophrenia aligning with reduced betaine levels. Data represent mean ± SEM. *p b 0.05; two-tailed Student's t-test. n = 29-31 in the control group, n
= 22-23 in the schizophrenia group, except for total GSH, total Cys, and total Hcy measurements, where n = 16-17 in the schizophrenia group was used. (k, l) Three postmortem
brain samples (SZ1, SZ5, and SZ12) from patients with schizophrenia revealed enhanced signals by anti-CEL antibody, while no statistical differencewas seen between control and schizo-
phrenia groups (l). Data represent mean ± SEM. *p b 0.05; two-tailed Student's t-test. n = 22 in the control group, n = 14 in the schizophrenia group.
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#SZ12) that showed a strong band (~30 kDa protein(s)) having Nε-
(carboxyethyl)lysine (CEL) (Figs. 7k and l), one of AGEs [12]. The
three samples showed betaine levels of below average (Fig. 7a), al-
though the correlation of the two measures (betaine levels and CEL
modification levels) did not fulfill a statistical significance possibly due
to the sample number limitation. This finding suggests a relationship
between elevated carbonyl stress and lowered betaine levels. Further-
more, these three patients displayed relatively high symptom scores
evaluated by using the Diagnostic Instrument for Brain Studies (DIBS)
[42] (Supplementary Table 13). Collectively, the results of postmortem
brain study highlighted the existence of a subset of patients withschizophrenia characterized by “betaine deficit-oxidative stress” pa-
thology, manifesting relatively severe psychotic symptoms.
3.11. Betaine's potency in alleviating carbonyl stress in GLO1-deficient
hiPSCs
Because coexistent betaine pathology and elevated carbonyl stress
were evident in a subset of schizophrenia cases, the efficacy of betaine
supplementation in mitigating the carbonyl stress in isogenic lines of
GLO1-deficient hiPSCs was tested. We firstly confirmed that there
were no missense variants in the genome of the subject (mentally
healthy) for the genes in the carbonyl stress pathway (Supplementary
Fig. 8. Betaine suppressed accumulation of advanced glycation products (AGEs) in hiPSCs and a genetic variant affected CHDH expression in brain. (a) Genomic structure of the human
GLO1 gene is schematically presented. Black and white boxes indicate coding and untranslated regions of exons, respectively. Three hiPSC lines for each genotype (WT-1-3 and KO-1-
3) were established. (b) Phase contrast images of WT-1 and KO-1 are presented. WT-2-3 and KO-2-3 showed morphology similar to WT-1 and KO-1 (data not shown). Scale bar: 400
μm. (c) Cell (WT-1 and KO-1) lysates were analyzed in western blotting using an antibody against carboxymethyllysine (CML), a typical type of AGEs. Note that the signal around
55 kDa (arrow head; “band A") was greatly enhanced by depletion of the intact GLO1 proteins. The filter was also probed with anti-GAPDH antibody as a loading control and anti-
GLO1 antibody to show a loss of the GLO1 protein in the GLO1 KO (−/−) cells. (d) KO-1 was cultured for four days in the absence or presence of indicated concentrations (5, 50, or
500 μM) of betaine. The results of western blot analysis of the cell lysates are presented (top). The position for “band A" is indicated by an arrowhead. The same experiment was
repeated using KO-2-3 and WT-1-3 in duplicate. A significant difference (n = six per group; 3 KO or WT lines × duplicate) was observed between the groups treated with 0 μM and
500 μM betaine. The CML signals were normalized to the intensity of GAPDH signals. Data represent mean ± SEM. *p b 0.05; Dunnett multiple comparison test. n = six. (e) Contents
of metabolites in the methionine-homocysteine cycle in the GLO1 KO hiPSCs. Data represent mean ± SEM. **p b 0.01, ***p b 0.001; two-tailed Student's t-test. WT-1-3 and KO-1-3
were triplicated (n=nine each). (f) CHDH variant, rs35518479, showed a significant association for its expression and SAM/SAH ratio in the brain, though betaine levels were unaltered.
Data represent mean ± SEM. *p b 0.05, **p b 0.01, ***p b 0.001; one-way ANOVA and two-tailed Student's t-test.
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444 T. Ohnishi et al. / EBioMedicine 45 (2019) 432–446Fig. 2). The GLO1-deficient hiPSC lines were prepared by harnessing the
CRISPR-Cas9 system, and they contained homozygous GLO1 KO alleles
(KO-1, KO-2 and KO-3) causing frameshift mutations in exon 1 and pre-
mature stop signals (Figs. 8a and b), and showed no protein expression
(Fig. 8c). As controls, three lines (WT-1, WT-2 and WT-3) were
established that were proven to harbor the normal GLO1 alleles. The
GLO1-deficient hiPSC samples displayed amajor band of ~55 kDa (called
“band A") with increased modification by carboxymethyllysine (CML),
another species of AGEs [12] (representative picture in Fig. 8c). When
betaine was added to cell culture, concentration at 500 μM significantly
suppressed the CML modification of “band A" (Fig. 8d), indicating
betaine's efficacy against elevated carbonyl stress. The GLO1-disrupted
hiPSCs showed comparable morphology (Fig. 8b) with those of the
WT, but they manifested reduced differentiation potential into neural
lineage, which could not be rescued by the betaine supplementation
(data not shown).
Next, we examined the effects of GLO1 ablation on the levels of beta-
ine and metabolites in the methionine-homocysteine cycle. Strikingly,
betaine levels were significantly decreased in the GLO1 KO hiPSCs com-
pared to the WT cells (Fig. 8e), suggesting that betaine is consumed to
cope with increased carbonyl stress. In parallel, lowered SAM/SAH
ratio concomitant with increased SAH levels in the KO cells was seen
(Fig. 8e), probably reflecting dampened intracellular homocysteine
clearance by BHMT pathway (Fig. 1) in the KO cells.
3.12. Pharmacogenetic evaluation of betaine efficacy in schizophrenia
We have revealed the differential efficacy for betaine in the mouse
strains with distinct genetic background (Fig. 5). Since a subset of
schizophrenia patients were characterized with betaine deficit-
oxidative stress pathology and the betaine treatmentwas effective in al-
leviating carbonyl stress, we speculated that the efficacy for betaine
might have a genetic predisposition. Cis- eQTL analysis of common ge-
netic variants in BHMT1, CHDH andGLO1 genes in postmortem brain tis-
sues revealed a significant association of a CHDH variant, rs35518479,
with its expression levels in the brain (p=0.03) (Fig. 8f, Supplementary
Figs. 10a and b). The A allele carriers showed a significantly higher
CHDH expression levels in the brain when compared to the G/G homo-
zygotes. Although there were no significant differences in betaine and
SAM levels according to the genotypes (Supplementary Fig. 10c), the
SAM/SAH ratio (methylation index) was higher in the A allele carriers
(p = 0.02) (Fig. 8f). The results suggest that CHDH expression levels
may affect the turnover rate ofmethionine-homocysteine cycle, and de-
pict a potential utility of CHDH-eQTL in stratifying schizophrenia pa-
tients for betaine treatment.
4. Discussion
In the present study, we provided a proof of concept for the potential
of betaine in the treatment of schizophrenia from the analyses of both
mouse and human samples, along with the identification of “betaine
deficit-oxidative stress” pathology in a subset of schizophrenia, which
may result in relatively severe symptoms. Our systematic examination
of betaine's role (see Supplementary Fig. 1) showed that the betaine's
action as a psychotropic is imparted partially through antioxidant/pro-
inflammatory effects. In addition, a regulation of DNA methylation ca-
pacity may be possible, from metabolomics/methylome analyses of
mouse and human samples. Notably, analyses of two different inbred
mouse strains highlighted an interaction of genetic background × drug
(e.g. betaine), and distinct pharmacogenetic profiles (e.g. MAP) accord-
ing to genetic background. Also, no differences in the brain betaine
levels were observed between the two strains, before and after betaine
supplementation (data not shown), ruling out strain (genetic) differ-
ences in brain betaine turnover.Although the more detailed mechanism of betaine's biological
effects remains to be clarified in the future study, it is worth noting
that methionine, the primary enzymatic product of BHMT
(betaine-homocysteine methytransferase), functions as a powerful anti-
oxidantmolecule. Furthermore, it shouldbepursuedwhether theexpres-
sional modulation of genes for antioxidant/proinflammatory cascades by
the betaine treatment is mediated via epigenetic changes elicited by the
methylation of histone or DNA, where SAM is used as a methyl donor.
Betaine, tri-methylglycine, is very simple in the chemical structure. It
receives step-wise breakdown to glycine in mammals: betaine to di-
methylglycine, di-methylglycine to mono-methylglycine, and mono-
methylglycine to glycine (Fig. 1). It is unlikely that these downstream
compounds may play a positive role to exert betaine's effect, because
di- and mono-methylglycine were under the detection limit (data not
shown) in mouse and postmortem human brain samples, probably
reflecting very rapid degradation of di-methylglycine into glycine by de-
methylation. In addition, the concentration of glycine seemed relatively
stable even by the manipulation of the Chdh gene or the supplementa-
tion of betaine in mice, excluding the idea stated above.
In this study, we detected a substantial accumulation in CEL adduct
of ~30 kDa protein(s) (Fig. 7k) and CML adduct of ~55 kDa protein
(s) (Fig. 8c) in postmortem brain and GLO1-KO iPSCs, respectively. It
was unexpected to see AGEs in a relatively protein-specific manner
under carbonyl stress, since the Maillard reaction (Supplementary
Fig. 2) is deemed to occur non-enzymatically [12]. Molecular identifica-
tion and characterization of the specifically modified proteins and the
mechanism of the specific modifications remain to be studied.
Although we did not address in this study, another known function
of betaine is osmotic regulation (Supplementary Fig. 1), and the deficits
in brain betaine levels may contribute to cellular osmotic perturbation
[6,7,43], which is reported to inhibit methionine uptake, inhibit protein
synthesis, and affect the mRNA translation by dysregulation of phos-
phorylation and mTOR signaling cascades [44–46]. These pathways
are shared with those identified in the transcriptomics analysis of
Chdh-deficient mice (Fig. 3f). Although taurine, myo-inositol, glycine
and glutamine are thought to play major roles as osmolytes in the
brain because of their higher cellular contents; betaine is favored in
neural cells as an osmolyte [6]. Thus, the osmotic issue should be pur-
sued in future studies.
Since betaine has already been approved as a therapeutic drug for
homocystinuria, an autosomal recessive inherited disorder due to a de-
ficiency of cystathionine beta synthase (CBS, Fig. 1) [47], it has the ad-
vantage of being repositioned for psychiatric illness. The utility is also
substantiated by our observation that betaine can penetrate the
blood-brain barrier and is well toleratedwith no serious adverse effects.
Interestingly, we identified an eQTL for CHDH expression, which
substantiates genotype-based stratification of schizophrenia patients
for betaine efficacy. Future studies are warranted to validate the utility
of “betaine deficit-oxidative stress pathology” as a biomarker and to
identify other genetic underpinnings for betaine's efficacy. It is also
worthwhile to test the availability of betaine in clinical setting for
schizophrenia and other neuropsychiatric conditions.
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